| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8958002 | Journal of Infection and Public Health | 2018 | 7 Pages |
Abstract
Overall assessment of clinical cure rate, microbiological eradication rate and safety assessment in this study has shown that CSE-1034 is an effective and safe option for the treatment of CAP patients of PORT risk III-IV. Moreover, the superiority of CSE-1034 over Ceftriaxone is also proven.
Related Topics
Health Sciences
Medicine and Dentistry
Infectious Diseases
Authors
Manu Chaudhary, Shiekh G. Ayub, Mohd A. Mir, for the protocol 05 group for the protocol 05 group,